首页> 外文期刊>Drug testing and analysis >Analysis of 30 synthetic cannabinoids in oral fluid using liquid chromatography-electrospray ionization tandem mass spectrometry
【24h】

Analysis of 30 synthetic cannabinoids in oral fluid using liquid chromatography-electrospray ionization tandem mass spectrometry

机译:液相色谱-电喷雾串联质谱法分析口腔液中的30种合成大麻素

获取原文
获取原文并翻译 | 示例
       

摘要

In recent years, the analysis of synthetic cannabinoids in human specimens has gained enormous importance in the broad field of drug testing. Nevertheless, the considerable structural diversity among synthetic cannabinoids already identified in 'herbal mixtures' hampers the development of comprehensive analytical methods. As the identification of the main metabolites of newly appearing substances is very laborious and time-consuming, the detection of the parent compounds in blood samples is the current approach of choice for drug abstinence testing. Whenever blood sampling is not possible however, the need for alternative matrices arises. In this article, we present a fully validated liquid chromatography-electrospray ionization tandem mass spectrometry (LC/ESI-MS/MS) method for the analysis of 30 synthetic cannabinoids in oral fluid samples collected with the Dr?ger DCD 5000 collection device. The method proved to be suitable for the quantification of 28 substances. The limits of detection were in the range from 0.015 to 0.9ng/ml, while the lower limits of quantification ranged from 0.15 to 3.0ng/ml. The method was successfully applied to 264 authentic samples during routine analysis. A total of 31 samples (12%) was tested positive for at least one of the following synthetic cannabinoids: AM-694, AM-2201, JWH-018, JWH-019, JWH-081, JWH-122, JWH-203, JWH-210, JWH-250, JWH-307, MAM-2201, and RCS-4. Given that stabilization of the collection pads after sampling is warranted, the collection device provides satisfactory sensitivity. Hence, whenever blood sampling is not possible, the Dr?ger DCD 5000 collection device offers a good tool for the analysis of synthetic cannabinoids in oral fluid in the broad field of drug testing.
机译:近年来,人体标本中合成大麻素的分析在药物测试的广泛领域中变得极为重要。然而,“草药混合物”中已经确定的合成大麻素之间相当大的结构多样性阻碍了综合分析方法的发展。由于鉴定新出现的物质的主要代谢物非常费力且费时,因此对血液样本中母体化合物的检测是药物禁忌症检测的当前选择方法。但是,无论何时无法进行血液采样,都需要使用替代基质。在本文中,我们介绍了一种经过充分验证的液相色谱-电喷雾串联质谱(LC / ESI-MS / MS)方法,用于分析使用Dr?ger DCD 5000采集装置采集的口腔液样品中的30种合成大麻素。实践证明该方法适用于28种物质的定量。检测限在0.015至0.9ng / ml的范围内,而定量下限在0.15至3.0ng / ml的范围内。该方法已成功应用于常规分析中的264个真实样品。对于以下至少一种合成大麻素,总共31个样品(占12%)被测试为阳性:AM-694,AM-2201,JWH-018,JWH-019,JWH-081,JWH-122,JWH-203, JWH-210,JWH-250,JWH-307,MAM-2201和RCS-4。考虑到采样后必须保证收集垫的稳定,收集装置可提供令人满意的灵敏度。因此,在不可能进行血液采样的情况下,Dr?ger DCD 5000采集设备为在广泛的药物测试领域中分析口腔液中合成大麻素提供了一个很好的工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号